Core Insights - The article discusses the transformation of China's pharmaceutical industry from "importing" to "exporting," highlighting the establishment of a dual "fast track" for international trade in innovative drugs and medical devices in the Boao Lecheng International Medical Tourism Pilot Zone [1][5]. Group 1: Event Overview - The China Innovation Drug and Medical Device Export Matching Conference was held on November 21, 2023, in Boao Lecheng, gathering nearly a hundred participants from government, industry associations, overseas hospitals, industrial parks, and pharmaceutical companies to explore new paths and opportunities for Chinese innovative drug and medical device exports [2]. - The conference featured companies like Su Sheng Biotechnology Co., which showcased advanced products such as platelet-rich plasma preparation devices and 3D-printed artificial bones, attracting interest from overseas clients [2]. Group 2: Market Dynamics - There is a growing international demand for high-quality Chinese pharmaceutical products, as indicated by the interest from neighboring countries in the medical tourism sector [3]. - The conference addressed barriers faced by domestic companies in international markets, such as unfamiliarity with policies, lack of channels, and difficulties in standard recognition, by integrating policy interpretation, resource matching, and product promotion [3]. Group 3: Strategic Importance of Lecheng - Lecheng is positioned as a key support in the transition of China's pharmaceutical industry, aiming to convert gathered international resources into development momentum for innovative pharmaceutical companies [4]. - The zone has established deep cooperative relationships with over 180 pharmaceutical companies from 20 countries and regions, including all top 30 global pharmaceutical firms [4]. Group 4: Future Outlook - The shift from a one-way "import" model to a two-way "export" model signifies Boao Lecheng's role as a bridge connecting China with the global market, fostering innovation and collaboration in the pharmaceutical sector [5].